促血管生长蛋白因子在心肌血运重建中给药路径的比较  

Comparison of Administration Pathways of Angiogenic Growth Factors in Myocardial Revascularization

作　　者：赵健[1] 王颖[1] 刘晓程[1] 

机构地区：[1]中国医学科学院中国协和医科大学泰达国际心血管病医院心外科,天津300457

出　　处：《心血管病学进展》2008年第2期326-328,共3页Advances in Cardiovascular Diseases

摘　　要：冠脉介入和搭桥手术挽救了大量冠心病患者的生命,但当血管发生弥漫性病变、桥血管再闭塞等情况时,上述治疗都难以实现完全血运重建。基于细胞水平的"分子血管搭桥术"通过注射心肌外源性促血管生长因子,诱导内皮细胞出芽和侧支循环重建。现就促血管蛋白因子给药的各种路径做一综述。Percutaneous coronary intervention （ PCI ） and coronary artery bypass grafting （CABG） have been used in the treatment of substantial patients with coronary heart disease. However, satisfactory PCI or CABG treatment is not available for many patients, because of the unfavourable characteristics such as diffuse coronary atherosclerosis or lack of suitable bridge vessels. ＂Molecular-bridge therapy＂ aims to induce therapeutic neovasculature and promote complete revascularization by supply of foreign growth factors. This review discusses and compares various administration pathways of angiogenic protein growth factors.

关 键 词：冠心病 心肌血运重建 促血管生长因子 路径 

分 类 号：R654.2[医药卫生—外科学]